

Proteomics launches diagnostic test leader 'PromarkerD'

20 March 2018 | News

Proteomics International is engaged with potential partners to bring PromarkerD to market in mainland USA, Mexico, Japan, Australia, China and Europe.



MedTech pioneer Proteomics International Laboratories Ltd has launched PromarkerD which is world leading predictive diagnostic test for diabetic kidney disease.

The pioneering diagnostic test was launched by Proteomics International partner Omics Global Solutions through its distributor in the Dominican Republic, Macrotech Farmaceutica, the exclusive provider of dialysis services in the country.

The successful launch represents the achievement of a key milestone in the stepped approach to commercialise the test in global markets using a range of technology platforms. Proteomics International is engaged with potential partners to bring PromarkerD to market in mainland USA, Mexico, Japan, Australia, China and Europe.

The test is being provided using the published mass spectrometry technology platform, known as a Laboratory Developed Test (LDT), and the Company expects to conclude its next licensing deal for this version of PromarkerD with a certified laboratory within weeks.

Proteomics International is focused on finalising the development of the in vitro diagnostic (IVD) immunoassay version of PromarkerD that can be used in clinical laboratories around the world.